Charles River Discovery Services has entered into an oncology biomarker research collaboration with Metabolon. The partnership combines Charles River’s preclinical oncology study expertise with Metabolon’s analysis of metabolic data to identify both mechanism of action and biomarkers.

Metabolon’s customized Metabolomics platform allows for quick validation of ideas and biomarker identification of mechanism of action. Together the companies will provide: elucidation, identification, characterization, and validation of drug target candidates, preclinical studies using validated in vitro and in vivo models, PK/PD, tumor growth delay, tumor growth inhibition, survival, combination and adjuvant study designs, assessment of lead chemistries, lead ID, optimal dose, optimal combinations, sensitivity/resistance patterns, and new indications for existing compounds, and development of biomarkers for preclinical PD, patient stratification/selection, translational models and efficacy.